Biomaterial Database

Effect of azidothymidine (AZT) on P24 antigen levels in patients with AIDS-related complex and AIDS. 1989

M M Reddy, and G McKinley, and A Englard, and M H Grieco

R.A. Cooke Institute of Allergy, St. Luke's-Roosevelt Hospital Center, New York, New York 10019.

Circulating HIV P24 antigen levels at baseline and following AZT therapy were measured in 9 patients with ARC and 11 patients with AIDS. Eight of these patients had no detectable levels of P24. The P24 antigen levels in the remaining 12 patients decreased significantly after AZT treatment. Following discontinuation of AZT treatment in 2 patients, the P24 antigen levels went up. These results clearly demonstrate the efficacy of AZT in reducing P24 antigen levels in circulation.

UI	MeSH Term	Description	Entries
D009894	Opportunistic Infections	An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.	Infection, Opportunistic,Infections, Opportunistic,Opportunistic Infection
D011020	Pneumonia, Pneumocystis	A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.	P carinii Pneumonia,P. carinii Pneumonia,P. jirovecii Pneumonia,PCP Pneumonia,Pneumocystis Pneumonia,Pneumocystosis,Pneumonia, Interstitial Plasma Cell,PCP Infection,Pneumocystis carinii Pneumonia,Pneumocystis jirovecii Pneumonia,Pneumonia, Pneumocystis carinii,Infection, PCP,P carinii Pneumonias,P. carinii Pneumonias,P. jirovecii Pneumonias,PCP Infections,PCP Pneumonias,Pneumocystis Pneumonias,Pneumocystoses,Pneumonia, P carinii,Pneumonia, P. carinii,Pneumonia, P. jirovecii,Pneumonia, PCP,Pneumonia, Pneumocystis jirovecii,Pneumonias, PCP
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163	Acquired Immunodeficiency Syndrome	An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.	AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000386	AIDS-Related Complex	A prodromal phase of infection with the human immunodeficiency virus (HIV). Laboratory criteria separating AIDS-related complex (ARC) from AIDS include elevated or hyperactive B-cell humoral immune responses, compared to depressed or normal antibody reactivity in AIDS; follicular or mixed hyperplasia in ARC lymph nodes, leading to lymphocyte degeneration and depletion more typical of AIDS; evolving succession of histopathological lesions such as localization of Kaposi's sarcoma, signaling the transition to the full-blown AIDS.	ARC,Lymphadenopathy Syndrome,AIDS Related Complex,Complex, AIDS-Related,Lymphadenopathy Syndromes,Syndrome, Lymphadenopathy,Syndromes, Lymphadenopathy
D012191	Retroviridae Proteins	Proteins from the family Retroviridae. The most frequently encountered member of this family is the Rous sarcoma virus protein.	Leukovirus Proteins,Retrovirus Proteins,Proteins, Leukovirus,Proteins, Retroviridae,Proteins, Retrovirus
D015215	Zidovudine	A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.	AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015488	HIV Antigens	Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.	AIDS Antigens,HIV-Associated Antigens,HTLV-III Antigens,HTLV-III-LAV Antigens,LAV Antigens,Lymphadenopathy-Associated Antigens,T-Lymphotropic Virus Type III Antigens, Human,HIV Associated Antigens,HTLV III Antigens,HTLV III LAV Antigens,Lymphadenopathy Associated Antigens,T Lymphotropic Virus Type III Antigens, Human,Antigens, AIDS,Antigens, HIV,Antigens, HIV Associated,Antigens, HIV-Associated,Antigens, HTLV III,Antigens, HTLV-III,Antigens, HTLV-III-LAV,Antigens, LAV,Antigens, Lymphadenopathy Associated,Antigens, Lymphadenopathy-Associated,Associated Antigens, HIV,Associated Antigens, Lymphadenopathy,III Antigens, HTLV
D016655	HIV Core Protein p24	A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by ELISA and Western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines.	HIV Major Core Protein p24,HIV gag Gene Product p24,HIV p24 Antigen,gag Protein p24, HIV,p24(HIV),HIV Protein p24,HTLV-III p24,p24 protein, Human Immunodeficiency Virus,HTLV III p24,p24 Antigen, HIV,p24, HIV Protein,p24, HTLV-III

Related Publications

M M Reddy, and G McKinley, and A Englard, and M H Grieco

Effect of azidothymidine on soluble CD4 levels in patients with AIDS or AIDS-related complex.

January 1990, Journal of clinical laboratory analysis,

M M Reddy, and G McKinley, and A Englard, and M H Grieco

Influence on survival of p24 antigen levels in patients with AIDS or advanced AIDS related complex treated with zidovudine.

December 1992, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,

M M Reddy, and G McKinley, and A Englard, and M H Grieco

Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine.

September 1990, AIDS (London, England),

M M Reddy, and G McKinley, and A Englard, and M H Grieco

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

July 1987, The New England journal of medicine,

M M Reddy, and G McKinley, and A Englard, and M H Grieco

The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

July 1987, The New England journal of medicine,

M M Reddy, and G McKinley, and A Englard, and M H Grieco

Azidothymidine steady-state pharmacokinetics in patients with AIDS and AIDS-related complex.

April 1989, The Journal of infectious diseases,